Evolution Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Evolution Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-173	Closed	-$17K	–	456
2021 Q3	$17K	Sell	173 -231	-57%	-$21.8K	﹤0.01%	333
2021 Q2	$39K	Hold	404	–	–	0.01%	229
2021 Q1	$39K	Sell	404 -23	-5%	-$2.41K	0.01%	221
2020 Q4	$41K	Buy	427 +38	+10%	+$3.67K	0.01%	192
2020 Q3	$37K	Buy	389 +4	+1%	+$463	0.01%	206
2020 Q2	$47K	Sell	385 -120	-24%	-$13.3K	0.02%	149
2020 Q1	$44K	Buy	505 +126	+33%	+$12.3K	0.02%	118
2019 Q4	$41K	Buy	379 +340	+872%	+$35.6K	0.01%	166
2019 Q3	$4K	Sell	39 -437	-92%	-$40.8K	﹤0.01%	321
2019 Q2	$40K	Buy	+476	New	+$39.1K	0.02%	92

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Evolution Wealth Advisors's NBIX Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 173 shares — an estimated $17K sold.

Evolution Wealth Advisors first reported a position in NBIX in Q2 2019 and held it in 10 quarters. The position peaked at $47K in Q2 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

Evolution Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 173 Neurocrine Biosciences shares in Q4 2021, an estimated $17K.
Evolution Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 10 quarters.
Evolution Wealth Advisors's Neurocrine Biosciences position peaked at $47K in Q2 2020.
405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.